Charlie Morris Appointed to Almac Group's Clinical Technologies Executive Team

12 December 2012: The Almac Group’s Clinical Technologies business unit is pleased to announce that Charlie Morris has joined the company as Vice President of New Products and Services. In this role, Mr. Morris will report directly to Jim Murphy, President of Almac Clinical Technologies, and will oversee the development of Almac’s IXRS® technology and enhance the company’s metrics-based discipline to the software development process.

Mr. Morris brings extensive experience in systems management and development to Almac. His varied background includes service in the financial services, government, and medical technology sectors. He has served in all stages of the systems development process, from inception to development to execution, and has significant experience managing international personnel.

Mr. Morris joins Almac after spending more than ten years serving as the Chief Technology Officer of Princeton Financial Systems (PFS), where he created and implemented multi-year IT strategic plans to grow and improve the PFS information technology infrastructure. He led a team of technical staff in the development, integration, and continuous improvement of a suite of investment accounting, compliance, and data warehousing applications to support financial services industry clients. Prior to his nearly two decades at PFS, Mr. Morris served as Director of Applications Development at Telescan Limited, building and implementing teleradiology systems. He began his career in military contracts where he developed flight simulation, anti-submarine warfare, and naval intelligence systems.

Jim Murphy, President of Almac’s Clinical Technologies business unit, comments on Mr. Morris’ appointment: “We are thrilled that Charlie Morris has joined Almac. He will be instrumental to the continued development of our IXRS® integrated web and phone-based platform. Given his breadth of system development leadership experience, we are highly confident in his ability to align the New Products and Services department to support accelerated innovation of Almac’s technology. We welcome Charlie to Almac and know he will have a profound impact on the expansion of our technology offerings and client relationships.”

About Almac Group

The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacturing, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.

The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Almac’s North American Headquarters is located in Souderton, PA. Almac’s Clinical Technologies business unit specializes in interactive technology and service solutions to increase the quality and efficiency of clinical trials. Our solutions include Interactive Voice and Web Response Systems (IXRS®) for patient randomization and drug assignment, patient and clinical supplies management, electronic-patient-reported-outcomes data collection, and Web drug reconciliation. Almac’s technologies have been deployed in over 1900 clinical trials, incorporating over 1.8 million patients in over 80 countries and in more than 60 languages.

For more information about the Almac Group, please visit www.almacgroup.com or e-mail info@almacgroup.com

Tristan Jervis

Managing Partner

Holborn Gate, 26 Southampton Buildings

London WC2A 1BP

Telephone: +44 (0)207 861 3838

Direct: +44 (0)207 861 3019

Fax: +44 (0)207 861 3839

E-mail: t.jervis@defacto.com

www.defacto.com

Back to news